Comparison of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in the Treatment of Multidrug-Resistant/Difficult-to-Treat Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-analysis.
Clin Infect DisSep 2, 2026
Milo Gatti, Riccardo De Paola, Beatrice Giorgi et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis compared the efficacy of ceftolozane-tazobactam and ceftazidime-avibactam in treating multidrug-resistant Pseudomonas aeruginosa infections. In a total of 1161 patients, ceftolozane-tazobactam demonstrated a higher clinical cure rate (OR, 1.82 [95% CI, 1.10-2.99]) compared to ceftazidime-avibactam, with no significant differences in other outcomes.
Key findings
- Ceftolozane-tazobactam showed a higher clinical cure rate than ceftazidime-avibactam (OR, 1.82 [95% CI, 1.10-2.99]).
- No significant difference in microbiological failure rates between the two treatments (OR, 0.66 [95% CI, 0.36-1.19]).
- 90-day resistance development rates were similar for both treatments (OR, 1.11 [95% CI, 0.51-2.42]).
- 30-day mortality rates did not differ significantly (OR, 1.00 [95% CI, 0.89-1.12]).
Why it matters
Understanding the comparative effectiveness of these treatments is crucial for clinicians managing multidrug-resistant Pseudomonas aeruginosa infections, as it can inform treatment decisions and improve patient outcomes.